Quoin Pharmaceuticals Ltd 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Quoin Pharmaceuticals Ltd 's ROA in the second quarter of 2026?
Quoin Pharmaceuticals Ltd recorded a cumulative net loss of $-19 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -104.52%.

However, within the Healthcare sector 793 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4361, from total ROA ranking in the first quarter of 2026 at 5041.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	36.1 %	22.12 %	-7.92 %	-44.98 %	-61.91 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-19	-17	-16	-14	-12
Return On Assets (TTM)	-104.52 %	-99.71 %	-96.9 %	-80.92 %	-63.66 %
QNRX's Total Ranking	# 4361	# 5041	# 4454	# 4456	# 4397
Total Assets (TTM) in million	12	16	33	10	9
Seq. Total Assets Change	-23.22 %	-50.8 %	217.82 %	13.35 %	-31.1 %
Seq. Net Income Change	-	-	-	-	-

QNRX's 5 Years Annual ROA >> Back to QNRX Management Effectiveness >> Compare QNRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 373
Sector	# 794
Overall	# 4331

Return On Assets Statistics
High	Average	Low
114.48 %	-64.29 %	-292.94 %
(Dec 31 2020)		(Sep 30 2022)

Financial Statements
Quoin Pharmaceuticals Ltd 's Assets	$ 12 million	QNRX's Balance sheet
Quoin Pharmaceuticals Ltd 's Income	$ -5 million	Quarterly QNRX's Income Statement
QNRX's Income by Division		See QNRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-7.92 %	33.72 %	-6.78 %	122.1 %	51.34 %
Total Assets in million	33	36	27	28	13
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-16	-9	-9	-9	-21
Annual Return On Assets	-48.32 %	-25.34 %	-32.76 %	-32.93 %	-167.32 %

QNRX's 5 Years Annual ROA >> Back to QNRX Management Effectiveness >> Compare QNRX ROA to its Competitors

More Return On Assets Ratios
QNRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
QNRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for QNRX's Competitors
Subscribers only: Roa for Quoin Pharmaceuticals Ltd 's Suppliers
Subscribers only: Return On Assets for QNRX's Customers

You may also want to know
QNRX's Roi	QNRX's Inventory Turnover Ratio	QNRX's Growth Rates	QNRX's Dividend Comparisons
	QNRX's Profitability Ratios	QNRX's Asset Turnover Ratio	QNRX's Dividend Growth
QNRX's Roe	QNRX's Valuation Ratios	QNRX's Financial Strength Ratios	QNRX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-16T08:52:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.